Why the study?
Anticoagulation therapy in patients with VTE and thrombophilia other than cancer or recurrence needed to be considered.
Does the presence of thrombophilia increase the risk of VTE recurrence in patients treated with DOACs?
Does the presence of thrombophilia increase the risk of VTE recurrence in patients treated with DOACs?
Patients with VTE and underlying thrombophilia, particularly cancer-associated thrombosis, have a higher tendency for recurrence despite DOAC therapy, necessitating individualized treatment durations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nakai et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: